MRK – Merck & Co., Inc.
Float Short %
Margin Of Safety %
13
Put/Call OI Ratio
0.6
EPS Next Q Diff
-2.76
EPS Last/This Y
1.32
EPS This/Next Y
-2.64
Price
109.18
Target Price
114.57
Analyst Recom
1.97
Performance Q
24.61
Relative Volume
0.68
Beta
0.29
Ticker: MRK
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | MRK | 106.83 | 0.63 | 0.24 | 657927 |
| 2025-12-29 | MRK | 106.65 | 0.63 | 0.54 | 646251 |
| 2025-12-30 | MRK | 106.09 | 0.69 | 0.64 | 627672 |
| 2025-12-31 | MRK | 105.28 | 0.69 | 0.92 | 633978 |
| 2026-01-02 | MRK | 106.49 | 0.69 | 0.25 | 637900 |
| 2026-01-05 | MRK | 107.43 | 0.70 | 0.99 | 630191 |
| 2026-01-06 | MRK | 108.81 | 0.70 | 0.21 | 637388 |
| 2026-01-07 | MRK | 108.62 | 0.67 | 0.49 | 668502 |
| 2026-01-08 | MRK | 110.99 | 0.67 | 0.53 | 687654 |
| 2026-01-09 | MRK | 110.45 | 0.67 | 0.33 | 711060 |
| 2026-01-12 | MRK | 109.22 | 0.68 | 0.41 | 697814 |
| 2026-01-13 | MRK | 108.26 | 0.67 | 0.61 | 701762 |
| 2026-01-14 | MRK | 111.01 | 0.67 | 0.50 | 705895 |
| 2026-01-15 | MRK | 110.93 | 0.67 | 0.33 | 712736 |
| 2026-01-16 | MRK | 108.85 | 0.66 | 0.60 | 728929 |
| 2026-01-20 | MRK | 109.47 | 0.60 | 0.52 | 563946 |
| 2026-01-21 | MRK | 111.09 | 0.60 | 0.34 | 570182 |
| 2026-01-22 | MRK | 109.16 | 0.60 | 0.24 | 573023 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | MRK | 106.85 | 19.4 | 4554.2 | 8.97 |
| 2025-12-29 | MRK | 106.66 | 19.4 | 4430.6 | 8.97 |
| 2025-12-30 | MRK | 106.08 | 19.4 | 4330.7 | 8.97 |
| 2025-12-31 | MRK | 105.29 | 19.4 | 4273.8 | 8.97 |
| 2026-01-02 | MRK | 106.49 | 19.4 | 4754.6 | 8.97 |
| 2026-01-05 | MRK | 107.42 | 19.4 | 4689.8 | 8.97 |
| 2026-01-06 | MRK | 108.89 | 19.4 | 4802.2 | 8.97 |
| 2026-01-07 | MRK | 108.59 | 19.4 | 4393.7 | 8.97 |
| 2026-01-08 | MRK | 111.00 | 19.3 | 5018.4 | 8.97 |
| 2026-01-09 | MRK | 110.51 | 19.3 | 4350.2 | 8.97 |
| 2026-01-12 | MRK | 109.20 | 19.0 | 4153.1 | 8.97 |
| 2026-01-13 | MRK | 108.26 | 18.8 | 4242.7 | 8.97 |
| 2026-01-14 | MRK | 110.99 | 18.8 | 5098.4 | 8.97 |
| 2026-01-15 | MRK | 110.96 | 18.8 | 4447.6 | 8.97 |
| 2026-01-16 | MRK | 108.83 | 18.9 | 3969.0 | 8.97 |
| 2026-01-20 | MRK | 109.47 | 18.3 | 4608.2 | 8.97 |
| 2026-01-21 | MRK | 111.10 | 18.3 | 4841.6 | 8.97 |
| 2026-01-22 | MRK | 109.18 | 17.0 | 4017.5 | 8.97 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | MRK | -0.63 | -1.32 | 1.50 |
| 2025-12-29 | MRK | -0.63 | -1.31 | 1.50 |
| 2025-12-30 | MRK | -0.63 | -1.31 | 1.50 |
| 2025-12-31 | MRK | -0.63 | -1.31 | 1.50 |
| 2026-01-02 | MRK | -0.63 | -1.31 | 1.50 |
| 2026-01-05 | MRK | -0.63 | -1.28 | 1.50 |
| 2026-01-06 | MRK | -0.63 | -1.28 | 1.50 |
| 2026-01-07 | MRK | -0.63 | -1.28 | 1.50 |
| 2026-01-08 | MRK | -0.63 | -1.28 | 1.50 |
| 2026-01-09 | MRK | -0.63 | -1.28 | 1.50 |
| 2026-01-12 | MRK | -0.63 | -1.32 | 1.50 |
| 2026-01-13 | MRK | -0.63 | -1.32 | 1.31 |
| 2026-01-14 | MRK | -0.63 | -1.32 | 1.31 |
| 2026-01-15 | MRK | -0.63 | -1.32 | 1.31 |
| 2026-01-16 | MRK | -0.63 | -1.32 | 1.31 |
| 2026-01-20 | MRK | -0.63 | -1.48 | 1.31 |
| 2026-01-21 | MRK | -0.63 | -1.48 | 1.31 |
| 2026-01-22 | MRK | -0.63 | -1.48 | 0 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.32
Avg. EPS Est. Current Quarter
2.05
Avg. EPS Est. Next Quarter
-0.44
Insider Transactions
-0.63
Institutional Transactions
-1.48
Beta
0.29
Average Sales Estimate Current Quarter
16185
Average Sales Estimate Next Quarter
15917
Fair Value
123.85
Quality Score
97
Growth Score
81
Sentiment Score
84
Actual DrawDown %
18.9
Max Drawdown 5-Year %
-43.4
Target Price
114.57
P/E
14.44
Forward P/E
20.18
PEG
2.25
P/S
4.24
P/B
5.24
P/Free Cash Flow
20.77
EPS
7.56
Average EPS Est. Cur. Y
8.97
EPS Next Y. (Est.)
6.33
Target Price Estimates Raised
2
Target Price Estimates Lowered
Profit Margin
29.79
Relative Volume
0.68
Return on Equity vs Sector %
9.5
Return on Equity vs Industry %
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
4017.5
Merck & Company, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 73000
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading